ArticleCurrent medical science2026
ATF6 Identification Sensitizes B-Cell Precursor Acute Lymphoblastic Leukemia Cells to Doxorubicin.
Article in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveActivating transcription factor 6 (ATF6) is a part of the unfolded protein response (UPR) system, which plays an important role in regulating endoplasmic reticulum stress. The overexpression of ATF6 has been reported in various malignancies; however, its expression and functional significance in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) are poorly understood.
methodsBone marrow samples from 69 pediatric patients with ALL (48 newly diagnosed, 21 relapsed) and peripheral blood/bone marrow samples from 29 nonleukemic healthy children (controls) were collected. To investigate the effect of ATF6 inhibition on the viability of BCP-ALL derived cell lines, NALM-6 and SUP-B15 cells were treated with the ATF6 inhibitor Ceapin-A7 both alone and in combination with doxorubicin. Apoptosis was quantitatively assessed using flow cytometry. The expression levels of ATF6, BCL-2 family members, and ATF6 target genes were determined by qRT-PCR, and the protein levels of ATF6, caspase-3, PARP, cell cycle regulators by Western blot analysis.
resultsOur results revealed that the ATF6 expression was higher in pediatric patients with relapsed ALL than in newly diagnosed patients. Furthermore, inhibition of ATF6 with Ceapin-A7 enhanced doxorubicin-induced apoptosis in the BCP-ALL cell lines NALM-6 and SUP-B15. Upon inhibition of ATF6, both BCP-ALL cell lines were arrested at the G1 phase of the cell cycle. Combined treatment altered the expression of apoptosis-related and cell cycle regulatory genes and proteins, and ATF6 target genes were upregulated by Ceapin-A7 alone but attenuated in the combined treatment group.
conclusionATF6 inhibition combined with doxorubicin represents a promising therapeutic strategy for enhancing apoptosis in BCP-ALL cells.
Indexed as
Identifiers
41801552What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.